Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731532 | 0.86 | GRIA4 (0.53) | GRIA2GRIA4ALDH1A1MAPK1 | |
| SCHEMBL623756 | 0.80 | L3MBTL1 (0.47) | GRIA2GRIA4GAAALDH1A1L3MBTL1 | |
| SCHEMBL3133960 | 0.77 | GAA (0.47) | GAAALDH1A1L3MBTL1NPSR1TSHR | |
| SCHEMBL1551473 | 0.73 | GRIA4 (0.46) | GRIA2GRIA4GAACCNCCDK8 | |
| SCHEMBL3404253 | 0.73 | GRIA4 (0.53) | GRIA2GRIA4GAAALDH1A1NPSR1 | |
| SCHEMBL3128132 | 0.73 | GRIA2 (0.42) | GRIA2GRIA4GAAALDH1A1L3MBTL1 | |
| SCHEMBL3404543 | 0.71 | GRIA2 (0.42) | GRIA2GRIA4GAAALDH1A1TSHR | |
| SCHEMBL4422079 | 0.68 | GRIA4 (0.51) | GRIA2GRIA4ALDH1A1MAPK1 | |
| SCHEMBL3206052 | 0.68 | GRIA4 (0.61) | GRIA2GRIA4ALDH1A1MAPK1 | |
| SCHEMBL6796039 | 0.66 | ALDH1A1 (0.58) | GRIA2GRIA4GAAALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250160-B1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARM INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2313399-B1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2313399-B1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8440664-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2250160-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009154741-A1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075951-A1 | Heteroaryls and uses thereof | PIK3R3, AKT1S1, PIK3R1 | GRIA2 2729/4885GRIA4 4190/4885GAA 2761/4885 |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | PIK3R3, AKT1S1, PIK3R1 | GRIA2 2729/4885GRIA4 4190/4885GAA 2761/4885 |
| US-20090325925-A1 | Thiophenes and uses thereof | PIK3CA, JAK2, MTOR | GRIA2 2570/4885GRIA4 2350/4885GAA 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.